ArticleArchives of dermatological research2025
Potential drugs associated with toxic epidermal necrolysis: a disproportionality analysis based on the FAERS database (2004-2024).
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A case of toxic epidermal necrolysis in an elderly female patient.SAGE open medical case reports · 2026Article
- Research progress on potential high-risk drugs for Stevens-Johnson syndrome and toxic epidermal necrolysis with insights from adverse drug reaction database mining.Frontiers in pharmacology · 2026Review
- Risk Factors for Drug-Induced Acute Generalized Exanthematous Pustulosis(AGEP) from 2004 to 2024: A Real-World Study Based on the FAERS.Clinical, cosmetic and investigational dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Toxic epidermal necrolysis (TEN) is a severe and potentially fatal skin reaction often associated with the use of multiple medications. Given the severity and potentially high fatality rate of TEN, identifying high-risk drugs is essential for improving clinical medication safety. The reporting odds ratio (ROR) was used to assess drug-related TEN reports in the FAERS database between Q1 2004 and Q3 2024. Univariate analysis, LASSO regression, and multivariate logistic regression were employed to explore the risk factors associated with drug-induced TEN. Bonferroni correction was applied for multiple comparisons. A total of 218 drugs were identified as being associated with TEN, including anticonvulsants (26/218), antibiotics (54/218), non-steroidal anti-inflammatory drugs (12/218), antineoplastic agents (3/218), and immunomodulatory drugs (8/218). Multivariate regression analysis revealed that the age group 37-66 years, as well as 26 specific drugs, including lamotrigine, phenytoin, carbamazepine, ciprofloxacin, sulfamethoxazole, and amoxicillin, might be risk factors factors for drug-induced TEN. These findings provide valuable insights to assist clinicians in early identification of drug-induced TEN, and offer a theoretical foundation for future drug safety evaluations and personalized treatment strategies.Constrained by the inherent limitations of disproportionality analysis, the current research findings on drugs related to TEN have a certain degree of uncertainty. Future research can utilize more advanced and rigorous research methods to earnestly explore the causal relationship between drugs and TEN.
Indexed as
Identifiers
40156759What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.